Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.04 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 6269
Sealed predictions
- AGFG1 in dopamine neurons, braak+0.51 (p 0.163) → +0.36 (p 0.336)receipt 6277
Swarm cases
receipt 6277: AGFG1 in dopamine neurons, braak
- power
- full sample +0.52 (p 0.026, n 18), 95% CI +0.07 to +0.80. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: +0.64 (p 0.0042, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.69 (p 0.0017, n 18). not the mix.
- skeptic
- leave-one-out range +0.46 to +0.65, sign flips 0; without severely affected donors +0.52 (p 0.026, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for AGFG1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts